Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 194.50
Bid: 193.00
Ask: 196.00
Change: 5.50 (2.91%)
Spread: 3.00 (1.55%)
Open: 186.00
High: 197.00
Low: 194.50
Yest. Close: 189.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs

18 Oct 19 13:20

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates

10 Oct 19 11:24

Avacta inks collaboration deal with ADC Therapeutics

(Sharecast News) - Biotechnology company Avacta Group has entered a collaboration and option agreement with ADC Therapeutics, which it described as a Switzerland-based clinical-stage oncology-focused biotechnology company pioneering the development of "highly potent and targeted" antibody-drug conjugates for patients suffering from haematological malignancies and solid tumours.

10 Oct 19 08:39

Avacta partners with Selexis ahead of first-in-human trials

(Sharecast News) - Avacta Group announced on Thursday that it has partnered with life sciences company Selexis to develop the Chinese hamster ovary (CHO) cell line, which will be used to manufacture Avacta's first 'Affimer' clinical candidate for first-time-in-human clinical trials.

20 Jun 19 10:28

Avacta Selects Candidate For First Human Trials Of Affimer Platform

LONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a

10 Jun 19 10:51

Avacta To Submit Application For TMAC Linker Testing In Tumours Study

LONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.The company, a

3 Jun 19 10:20

Avacta falls as stuttering revenues exacerbate losses

(Sharecast News) - Avacta Group's shares slid on Tuesday as interim revenues dropped on the back of a lower contribution from the life sciences division, which resulted in wider losses.

9 Apr 19 12:11

Avacta shares fall as interim revenues slide

(Sharecast News) - Biotherapeutics and research reagents developer Avacta Group reported a fall in half-year revenues to £1.0m on Tuesday, from £1.5m a year earlier.

9 Apr 19 10:37

Avacta Shares Fall On Widened Interim Loss, Lower Revenue

LONDON (Alliance News) - Avacta Group PLC on Tuesday reported a widened first half loss mainly due to lower income contribution from life sciences unit.The stock was trading 8.5% lower on a

9 Apr 19 09:49

Avacta Hires IP Group Unit Boss Sam Williams As Non-Executive Director

LONDON (Alliance News) - Avacta Group PLC on Monday said it has appointed Sam Williams as a non-executive director with immediate effect.The biotechnology company said Williams is currently

28 Jan 19 12:01

Avacta Group makes solid development progress

(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on its trading on Monday, as investors gathered for its annual general meeting.

21 Jan 19 12:14

IP Group Builds Over 17% Holding In Biotechnology Firm Avacta (ALLISS)

LONDON (Alliance News) - Avacta Group PLC on Thursday said IP Group PLC now holds 17.2% stake in the biotechnology company following a transaction on December 18.Prior to that, IP holding

3 Jan 19 11:34

Avacta Group Appoints Roche's Jose Saro As Chief Medical Officer

LONDON (Alliance News) - Reagents developer Avacta Group PLC on Wednesday appointed Jose Saro as chief medical officer to lead the firm's therapeutic development strategy.Saro brings 20

12 Dec 18 11:14

Avacta Group picks up Jose Saro as chief medical officer

(Sharecast News) - Biotherapeutic development company Avacta Group announced on Wednesday that Dr Jose Saro has been appointed as its chief medical officer, to lead its therapeutic development strategy and drive the in-house programmes into the clinic.

12 Dec 18 09:45

IP Group Investee Teams With LG Chem To Develop Affimer Drug Candidate

LONDON (Alliance News) - IP Group PLC on Monday said its portfolio company Avacta Group PLC signed a development & license deal with LG Chem Life Sciences.IP Group currently holds a in

10 Dec 18 08:52

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.